Page 1
Cedars-Sinai
Technology
Health Ventures
IMPACT
REPORT
2026
Page 1 of 31
⇩ Download PDF
Use the arrow keys, swipe, or the thumbnails below to navigate.
Page 2
WELCOME IMPACT
REPORT
2026
From Technology Transfer to Transformative Innovation
At Cedars-Sinai, our mission—to deliver exceptional care enhanced by research and education—
demands continuous innovation. What began as a traditional technology transfer office has
evolved into a multifaceted enterprise designed to accelerate that innovation at every stage.
CONTENTS
Today, Cedars-Sinai Technology & Health Ventures provides not only core technology transfer Structure . . . . . . . . . . . 3
services, but also advanced financial and venture capabilities that help transform ideas into Real-World
Impact . . . . . . . . . . . . 4
market-ready solutions. Our teams pursue opportunities beyond the scope of traditional models—
Strategy . . . . . . . . . . 6
forming creative partnerships across the United States and internationally, and identifying Portfolio . . . . . . . . . . . 7
pathways for innovations that might otherwise remain in the lab. Discoveries that once risked
Technology
stalling now have the support, strategy and capital required to move forward as new treatments, Ventures . . . . . . . . 9
diagnostics and tools for patient care. Financial
Snapshot . . . . . . . . 10
This integrated approach brings together three complementary strengths: translating discoveries into Case Studies . . . . . . 11
real-world applications, advancing early-stage ideas through structured venture-building, and investing JAMES D. LAUR, JD Accelerator . . . 16 +
in high-potential companies positioned for scale. Engaging innovators across the full spectrum—from Senior Vice President, Case Studies . . . . . . 17
Intellectual Property and
early insight to clinical adoption—helps us maximize the potential for meaningful impact.
Health Ventures
Health
Our evolution reflects a deliberate shift: from managing intellectual property to actively shaping Ventures . . . . . . . 23
the future of healthcare. By aligning scientific discovery with clinical insight and market strategy, Case Studies . . . . . 24
we are better positioned to move promising ideas forward—faster, and with greater impact.
Team . . . . . . . . . . . . 29
Global Impact . . . . 30
Our work remains tightly connected to the Cedars-Sinai mission. Every partnership we form
DAVID M. WRIGLEY
and every innovation we advance is grounded in a single objective: improving patient outcomes.
Executive Vice President
As we look ahead, we remain committed to accelerating ideas that matter—ensuring more and Chief Financial Officer,
breakthroughs reach the patients and communities who need them most. Cedars-Sinai Health System
2
Page 3
PORTFOLIO
INNOVATIONS
TECHNOLOGY VENTURES (Biotech, Medtech, Early Stage, LP) HEALTH VENTURES (Health Tech, Series A)
Invention Product Company Initial Testing with More Pivot if Secure Expand Enter New
Conception Formation Product Early Users Testing Necessary Additional Team Markets
Patent Development Funding
Initial Secure Early MVP User Iterate Grow Add New Grow and
Validation Funding Release Feedback Based on Customer Partners and Repeat
Feedback Base Channels
IDEATION CREATION VALIDATION ITERATION SCALE EXPANSION
Cedars-Sinai Technology Ventures Cedars-Sinai Accelerator + WHAT WE DO : Cedars-Sinai Health Ventures
SUPPORT FOR : WHAT WE DO : SUPPORT FOR :
● Provide stakeholder feedback on SUPPORT FOR : WHAT WE DO :
product/market fit and business
Very early companies exploring ● Provide commercial Companies that have developed Companies which have already ● Provide clinical and stakeholder
case
a product idea or building the assessment and technical an initial product and are ready to raised a significant amount of feedback on product, business
first version of a product, as support for product enter the B2B market. The founding
● Give access to a broad user base funding but are looking to scale case and messaging
well as new technologies that development team is in place and has typically to drive product improvement and their product or to target larger ● Invest primarily in Series A
need a core team and initial raised some seed funding to support iteration customers. These companies
● Initial investment or connection and B rounds
funding. Many internal innovation to pre-seed/seed venture the product launch. The company ● Give guidance on sales process typically have initial market
● Make introductions to other
initiatives at Cedars‑Sinai fit into investors often has a small number of early and cycle validation. Cedars-Sinai is a key
health system customers and
this category. customers. ● Refine messaging on value customer.
● Guidance on defining mission, to an established network of
overall strategy, proposition to resonate with target venture firms
and key milestones customers
3
Page 4
PORTFOLIO IMPACT
REPORT
2026
INNOVATIONS
Cedars-Sinai’s unique innovation ecosystem Changing Lives Spotlight
translates discovery into real-world impact, delivering Collectively, companies within our
The Frykman-
portfolio have helped improve care for
high-quality care for all with equity and compassion. countless individuals—reaching patients Kimble Stimulator
Our investments advance patient care, accelerate research and strengthen through a range of clinical, operational is a low-cost, effective
communities worldwide, moving breakthrough therapies, medical devices and and integrated health solutions. pediatric surgical
nerve stimulator
digital health solutions from the lab to clinical and commercial settings—and improving
outcomes for patients far beyond Cedars-Sinai’s campuses.
Creating Jobs developed at
Many of the companies we partner with Cedars-Sinai by
concentrate on equipping clinicians and Drs. Philip Frykman
The global impact of this work helps shape standards of care, fuels new industries
care teams, reinforcing the workforce and Keith Kimble to
and reinvests resources into research and education, creating a virtuous cycle that
capacity required to meet growing treat children with life-
benefits patients, clinicians and communities across the world. threatening anorectal
demand for healthcare services. These
innovations are creating jobs around malformations (ARM).
As it transforms biomedical discoveries and the globe. Cedars-Sinai
innovations, our portfolio also generates income Technology Ventures
Improving Efficiency
that is reinvested directly into Cedars-Sinai’s mission, In parallel, technology-enabled
provided key support
and indispensable
reinforcing a sustainable cycle of innovation and impact. These returns help support solutions are accelerating diagnosis resources to develop
ongoing research, clinical excellence, community health and education—fueling and clinical decision-making, helping the technology.
new discoveries, advancing patient care and strengthening the academic and clinical clinicians identify disease earlier and The device has since
environment that makes future breakthroughs possible. By reinvesting innovation- begin appropriate treatment sooner. enabled local surgeons
These advances reduce delays in
driven revenue back into the institution, Cedars-Sinai ensures that success in to perform surgery on
care, improving efficiency and tens of thousands of
the marketplace translates into lasting benefit for patients, clinicians and the
supporting more timely, effective children who would
communities we serve. clinical interventions. have otherwise gone
without.
4
Page 5
REAL-WORLD IMPACT
REPORT
2026
IMPACT
278 161 70
Spotlight
Research Tools
Accelerating Under the leadership
Translation of Eduardo Marbán,
Treatments or Drugs Advanced Diagnostics or Tests Developed The portfolio also includes 70 research MD, PhD, Cedars‑Sinai
Across the portfolio, 278 treatments and Portfolio companies are strengthening the tools that help bridge the gap between advanced the
drug programs are moving forward with ability to detect disease earlier and more discovery and patient care. By development of
a clear focus on patients—bringing new accurately with 161 diagnostics and tests streamlining experimentation, validation cardiosphere-derived
and improved treatment options closer to developed or in use. These tools support and data analysis, these tools accelerate cells (CDCs), an off-
the people who need them most. These prevention and early intervention by helping the transition from laboratory findings to the-shelf therapy
efforts address diseases with few effective clinicians identify risk, confirm diagnoses clinical application—shortening timelines designed to reduce
therapies today, offering the potential for sooner and guide timely treatment—often and enabling researchers to deliver inflammation, repair
better outcomes, fewer side effects and an before conditions become more complex or real-world impact more efficiently. tissue and improve
improved quality of life. costly to manage. function in serious
disease. Originally
106 151 9
developed by
Marbán at Johns
Countries Served Hopkins University,
Through a growing global the technology
footprint, portfolio companies and additional
Medical Devices Brought to Market Digital or Software Solutions Deployed extend beyond a single region, supporting intellectual property
Portfolio efforts extend into device The portfolio includes 151 digital and software- care delivery, clinical research and are licensed to
development, where emerging therapies based solutions designed to support operational innovation in nine countries. Capricor Therapeutics
advance toward clinical use with the healthcare providers and care teams. These Their presence demonstrates scalability for clinical and
potential to address unmet medical technologies improve clinical workflows, across diverse healthcare systems, commercial
needs and improve outcomes for patients decision-making and system integration, expands access to diagnostics and development.
worldwide. These new devices were reducing administrative burden, enhancing treatments, and strengthens collaboration
brought to market, addressing diseases efficiency and allowing clinicians to spend with research institutions and industry
that affect millions of people worldwide. more time focused on patient care. partners worldwide.
5
Page 6
STRATEGY IMPACT
REPORT
2026
Cedars-Sinai’s investment strategy is built on the To execute on this investment philosophy,
we operate through two complementary
foundation of advancing healthcare innovation investment arms, each tailored to specific
while maintaining alignment with our health system’s mission. Across both of our stages and sectors within the healthcare
investment arms, we prioritize partnerships with founders who demonstrate exceptional innovation ecosystem.
execution capabilities and a deep understanding of the healthcare landscape.
Cedars-Sinai Cedars-Sinai
Technology Ventures and Health Ventures seek companies that offer breakthrough Technology Ventures
(CSTV) supports early-stage healthcare
Accelerator
supports the growth
+
solutions with strong founder-market fit and clear strategic alignment with
and life science startups aligned with and development
Cedars-Sinai, either today or in the future. Given the critical nature of healthcare
Cedars-Sinai’s mission and where we of early-stage
innovation, we value founders who understand sustainable growth, positive unit can provide meaningful operational companies focused
economics, and the unique challenges of bringing healthcare solutions to market. support. on improving
We look for visionary leaders who can execute on their bold ideas in a targeted, healthcare and
disciplined manner. Cedars-Sinai healthcare delivery
Health Ventures through mentorship,
We evaluate potential investments based on four core criteria: (CSHV) is the strategic venture arm of financial investment,
Cedars‑Sinai, investing primarily in and access to our
e Strategic fit with Cedars-Sinai either today or in the future Series A software, AI, HCIT, and tech- health system. Startups
enabled services companies with clear receive support, with
e First-in-class, best-in-class, breakthrough solutions
product–market fit and strong strategic defined milestones
e Strong founder market fit alignment. and a curated
e Revenue and market traction, as well as growth potential curriculum including
specialized workshops
and sessions.
Portfolio Value FY 2026 (INCLUDING EXITS)
$1.14 billion
6
Page 7
PORTFOLIO
VENTURE VENTURE
DEVELOPMENT BUSINESS UNITS VENTURE UNITS CREATION
Our investment portfolio embraces the full
spectrum of innovation in the healthcare
WHOLLY OWNED
space, from basic research to consumer-
facing technology, including:
MOLECULES CARE MANAGEMENT
PHARMACEUTICALS SUPPLY CHAIN
MANAGEMENT
BIOTECHNOLOGY
SELECTED REVENUE CYCLE
PORTFOLIO LP MEDICAL DEVICES
COMPANIES INVESTMENTS CYBERSECURITY
ARTIFICIAL
INTELLIGENCE/ BUSINESS/
MACHINE LEARNING ADMINISTRATIVE
SOLUTIONS
GENOMICS/GENETICS
DECISION SUPPORT WELLNESS AND
FITNESS APPS
DIGITAL HEALTH
PHRS/PERSONAL
CARE DELIVERY HEALTH MANAGEMENT
MODELS
EXITED
7
Page 8
Why
Cedars-Sinai?
With 1.85 million
outpatient visits, 50,000
admissions and 125,000
emergency visits annually,
Cedars‑Sinai has the
patient volume and clinical
complexity to identify
meaningful programs, pilot
new solutions and validate
innovations in real-world
settings.
8
Page 9
TECHNOLOGY
VENTURES
Cedars-Sinai Technology Ventures
“ The journey from
laboratory breakthrough to
bedside impact is complex, with
challenges that capital alone
(CSTV) is the early-stage investment arm of Cedars-Sinai, focused
on healthcare and life science startups across med tech (devices and
cannot solve. Our approach
diagnostics), biotech (drug discovery programs) and health tech goes beyond investment.
(regulated digital health). CSTV typically invests in companies at the
pre-commercialization stage that align with Cedars-Sinai’s mission to We partner with early-stage
advance healthcare and improve patient outcomes. innovators to provide the
Our focus is on companies in which we can provide operational clinical expertise and strategic
support across regulatory pathways, pricing strategies, reimbursement
planning, pilots and enterprise-wide contracts. With more than infrastructure needed to
$230 million invested in the portfolio to date, we invest off the balance
sheet of Cedars‑Sinai Health System. We don’t require revenue traction
pre-investment but look for strong founder-market fit and breakthrough
“
advance development and
deliver meaningful impact
technology potential. We can lead, co-lead or follow in rounds, for patients.
maintaining long-term commitments until companies achieve their
intended outcomes.
NIRDESH GUPTA, PhD
Managing Partner,
Cedars-Sinai
Technology Ventures
9
Page 10
FINANCIAL IMPACT
REPORT
2026
SNAPSHOT
$142
Companies by Sector
As a nonprofit
institution,
Cedars-Sinai
reinvests
million 19
the revenue
generated
through
Health Tech intellectual
in licensing revenue in the last 5 years property into the
14
Projected similar licensing income through 2030 health system
to help advance
research,
30%
innovation and
Med Tech future discovery.
of portfolio 18
Bio Tech
is licensed or optioned
10
Page 11
CASE STUDY IMPACT
REPORT
2026
PROMETHEUS
$10.8 BIOSCIENCES
billion
VALUE AT EXIT Focus Area Therapeutics for IBD
Category Precision Medicine
Unique Value
e Combines machine learning-
based analytics with the
“ Anti-TL1A
therapy is a
world’s largest IBD biobank. very promising
Opportunity The global IBD treatment
market is valued at mechanism for
Prometheus’s Early Wins
$10.8 billion $22.3 billion.
e Positive clinical trial results
the treatment of
acquisition by
Merck was among Prometheus Biosciences is a clinical-stage
were shown across multiple IBD, and everyone
the largest biotech
deals of 2023,
biotechnology company specializing in precision
antibody treatment has been waiting
candidates.
validating the medicine for immune-mediated diseases, for companion
precision IBD space particularly inflammatory bowel diseases (IBD) e PRA023, a TL1A-targeting
commercially.
like ulcerative colitis and Crohn’s disease. Utilizing
diagnostic
Cedars-Sinai’s antibody, received FDA
nearly $800 their proprietary Prometheus360 platform, IND acceptance in late directed therapy
million return
demonstrated
the company combines machine learning- 2020, triggering rapid that will allow us
based analytics with extensive gastrointestinal development for ulcerative
that startup
bioinformatics to identify novel therapeutic
to treat the right
companies from colitis and Crohn’s disease.
academic medical targets. In 2023, Merck acquired Prometheus patient with the
”
centers that have
been derisked
Biosciences for approximately $10.8 billion. Social Impact right drug.
before spinning out e Moved treatment from trial-
can generate
and-error toward precision William Sandborn, MD
transformative Cedars-Sinai Involvement
medicine, offering new hope Chief of Gastroenterology and
financial outcomes. Prometheus Therapeutics was built on intellectual
for remission among patients. Director, IBD Center, UC San Diego
property exclusively licensed from Cedars-Sinai,
External clinical investigator,
$40
rooted in more than two decades of research led
by Dr. Stephan Targan, Dr. Dermot McGovern and the institution’s IBD
Financial Impact Prometheus ARTEMIS-UC Trial
e Analysts project the TL1A
biobank. Cedars‑Sinai remained deeply engaged
million as a strategic investor, with board representation
antibody class could
generate billions in annual
INVESTED and ongoing scientific collaboration that helped
revenue.
guide the company’s development.
11
Page 12
CASE STUDY IMPACT
REPORT
2026
GRAVIDAS
DIAGNOSTICS
Focus Area Preeclampsia Diagnostic
Category Women’s Health
Unique Value
e Low-cost, rapid and usable
at home, it enables proactive
“ Pregnant
women with
intervention before life- risk factors and
Opportunity Preeclampsia impacts
~ 5-8% of all pregnancies
threatening symptoms develop. limited access
in the U.S. resulting in
Early Wins to routine
200,000 cases per year.
e In 2024, Gravidas Diagnostics obstetric
Gravidas Diagnostics’ rapid point-of-care
was awarded a $3 million care will be
federal grant from ARPA-H.
The Gravidas test could reduce reliance on (POC) test is designed to improve pregnancy the largest
a battery of tests, including blood pressure outcomes. The assay identifies individuals at risk e Gravidas Diagnostics is working
measurement, urine protein testing, blood
for severe preeclampsia— a condition affecting
beneficiaries
toward submitting a 510(k)
chemistry panels and clinical assessment of
approximately 5–8% of pregnancies in the application to the FDA of this home-
”
maternal symptoms.
United States —addressing a critical unmet need to bring its test to market. based test.
and with the potential to reduce maternal and
fetal morbidity and mortality worldwide. Social Impact Sarah J. Kilpatrick,
e An affordable, at-home test MD, PhD
Cedars-Sinai Involvement could democratize early Chair, Department of
detection, reduce racial Obstetrics and Gynecology
Gravidas was spun out of Cedars-Sinai
Cedars-Sinai
Medical Center based on licensed technology disparities and reach women in
developed through research led by communities who lack regular
Drs. Ravi Thadhani, Anders Berg and Ananth obstetric access.
Karumanchi, whose multicenter study
supported FDA approval of a blood test for Financial Impact
preeclampsia. Cedars-Sinai continues to e Early preeclampsia intervention
support the company through its intellectual reduces costly emergency
property arm and ongoing research hospitalizations, ICU admissions
collaboration. and NICU stays.
12
Page 13
CASE STUDY IMPACT
REPORT
2026
Targeting JUPITER
Cavalry NRF2-dependent
cancers
BIOVENTURES
Focus Area Drug Development
Category Precision Medicine
Unique Value
e Vertical integration: Company
development, capital infusion,
“ Mayo Clinic
is committed
and scientific incubation all exist to producing
Opportunity The “science first, fail fast”
model aims to reduce
under one roof. meaningful,
the time and cost of
Early Wins effective change
getting novel therapeutics
e The company raised an initial that transforms
to patients.
Engineering
$70 million from a strong health and
syndicate of biotech investors.
Ganymede targeted Jupiter Bioventures is a biotech venture- medicine. Clinical
growth factors foundry deploying a “science first” model in e Successfully validated its first
which it evaluates promising scientific ideas, or
excellence requires
“Moon” concepts through preclinical
“Moons,” de-risks them through early-stage proof-of-concept studies. continual discovery,
seed investments and experimentation, and translation and
scales the most promising ones into fully Social Impact
independent therapeutic companies. Jupiter
innovation. We’re
e This approach has the potential to
brings together scientists, entrepreneurs and generate multiple new medicines for eager to see what
investors under one collaborative model. cancer and diseases where cancer innovations show
biology provides insight, particularly
promise through
conditions with significant unmet
Cedars-Sinai Involvement
need and large patient populations. this unique biotech
”
Cedars-Sinai Technology Ventures is a
Best-in-class co-founding investor in Jupiter’s $70 million model.
Persistence in vivo inaugural fund. Cedars-Sinai holds a seat
Financial Impact
CAR T therapies e The foundry model is designed to Vijay Shah, MD
on the board.
achieve higher capital efficiency Kinney Executive Dean for
than traditional venture models Research, Mayo Clinic
by de-risking early and scaling Co-founding investor in
Jupiter Bioventures
only validated science.
13
Page 14
CASE STUDY IMPACT
REPORT
2026
MITERA BIOSCIENCES
“
IL-35 Unique Value The biology
Focus Area Autoimmune disorders;
Various regulatory mechanisms e Mitera’s approach could
Transplant rejection
enable lasting immune underlying
a
Category Therapeutic Development tolerance rather than blunt Mitera’s pursuit
systemic suppression.
Opportunity Developing safer and more is really new.
effective therapeutics
Early Wins While there’s
derived from our innate
immune system.
e The company raised a clear potential
$2 million seed SAFE financing
Regulatory Effector for treating
T cell T cell including over $1 million
Mitera Biosciences is developing groundbreaking
from Cedars-Sinai Health transplant
b investigational therapeutics with a novel
mechanism of action leveraging three key
Ventures. patients, the
? ? features: (1) impairment of effector T cells (Teffs); therapy could be
Social Impact
(2) proliferation of regulatory T cells (Tregs); and
e Current immunosuppressants used for so many
(3) downregulation of B cell activation, proliferation,
and antibody production. This combination of
require lifetime monitoring bigger, broader
? and cause serious side
attributes is highly unique and could provide diseases out
effects. Mitera’s natural-
effective and well tolerated therapeutics for patients
protein approach could there, and that’s
”
in need, if successful in future clinical studies.
dramatically improve really exciting.
c IL-35 and
others? quality of life for transplant
Cedars-Sinai Involvement recipients and autoimmune Kevin Chow, PhD
Mitera was founded on intellectual property patients. Co-founder, President and CEO,
? ? Mitera Biosciences
exclusively licensed from Cedars-Sinai,
which also provided initial seed funding. Financial Impact
Co-founder Dr. Stanley Jordan serves as e Autoimmune diseases and
Director of the Kidney Transplant Program organ transplant rejection
at Cedars-Sinai. Co-founder Dr. Ananth cost over $100 billion
IL-35 and Karumanchi conducts research at Cedars-Sinai annually in U.S. care.
others? as a collaborator.
14
Page 15
CASE STUDY IMPACT
REPORT
2026
GEMELLI BIOTECH
Focus Area Gastrointestinal disease
Category Precision Diagnostics
Unique Value
e Gemelli transformed how IBS is
diagnosed with tests that address
“ “I’m just
very thankful
a 40 to 60% misdiagnosis rate in for it because
Opportunity IBS affects ~800 million
people globally and
functional GI disorders. I am starting
~35 million in the U.S.
Early Wins to feel better
Trio-Smart® measures Gemelli Biotech is a precision diagnostics
e The company launched its first for the first
the levels of hydrogen,
company focused on advancing the
diagnostic, ibs-smart®, a blood test time in over
”
methane and hydrogen
that helps move IBS diagnosis from
sulfide to provide you with understanding and diagnosis of functional
exclusion to causality.
five years.”
a more complete picture of GI disorders. Founded out of research from
gut health.
Cedars‑Sinai, the company develops non- e Its second test, trio-smart®, is a Sarah
invasive tests that measure key biomarkers to breath test designed to provide IBS patient using Gemelli
provide clearer insights into conditions like a fuller picture of gut microbiome Biotech’s diagnostic testing
IBS and SIBO. Gemelli aims to improve patient gases.
outcomes and reduce costs for clinicians and
payers. Social Impact
e Patients get faster diagnoses and
Cedars-Sinai Involvement targeted treatment—especially
Both ibs-smart® and trio-smart® were women, who are often overlooked
developed in partnership with Cedars-Sinai’s despite being disproportionately
MAST (Medically Associated Science and affected by IBS.
Technology) program. Dr. Mark Pimentel, a
co-founder and scientific advisor, helped lead Financial Impact
a 2,500-patient study at Cedars-Sinai from e With IBS costing the U.S. healthcare
which the tests emerged. Cedars-Sinai has system billions annually, precision
participated in funding rounds. diagnostics represent major cost
savings for payers, patients and
providers.
15
Page 16
ACCELERATOR +
Nothing is worse for a mid-stage
“ Every startup faces
its own mix of funding,
clinical and infrastructure
challenges on the road
company than a premature ‘no.’ to commercialization and
The Cedars-Sinai Accelerator+ program allows clinicians from
the Cedars-Sinai Health System and key opinion leaders to engage, addressing unmet patient
providing feedback and guidance. The program represents the
needs. Our role is to partner
evolution of our proven accelerator model into a comprehensive
venture-building platform for Seed+ and Late Seed healthcare with them and provide
companies advancing toward commercialization. We partner
bespoke guidance throughout
directly with startup teams, providing capital investment, clinical
and market expertise and guaranteed fast-track evaluation for
product development within the Health System and beyond, by
providing qualified connections into a national network of academic
“
their journey at Cedars-Sinai
and across the broader U.S.
medical centers who are looking to implement new solutions in healthcare system.
their institutions. Our rolling program delivers real-world validation,
streamlines clinical integration, and provides strategic guidance to
scale innovation and, ultimately, improve patient outcomes. KINSHUK KOCHER, MBA
Director, Venture Investing,
Cedars-Sinai Technology Ventures
KEVIN WINSTON
Director, Business Development
and Programs,
Cedars-Sinai Technology Ventures
16
Page 17
CASE STUDY IMPACT
REPORT
2026
SYNTHO.AI
Focus Area Data Privacy and
Protection
Unique Value
e Syntho enables researchers
and developers to work with
“ The use
of synthetic
Category Data, Synthetic Data realistic datasets without the data reflects
Opportunity Data initiatives require
months-long approval processes our pursuit of
associated with real patient
secure access to data,
data, thus removing a critical
cutting-edge
which demands significant
Synthetic data can bottleneck in healthcare AI technologies
simulate a wide variety time and resources.
of edge cases and real-
development. to advance
world scenarios early in
development, helping to
Syntho.ai is an Amsterdam-based company
Early Wins medical research
revolutionizing the tech industry with
identify bugs and issues
e Winner, Philips Innovation Award. and improve
”
before they escalate. AI‑generated synthetic data. As the leading
provider of synthetic data software, Syntho’s e Winner, NL Startup Competition. patient care.
mission is to empower businesses worldwide to
e Winner, Global SAS Hackathon.
generate and leverage high-quality synthetic Craig Kwiatkowski,
data at scale. PharmD
Social Impact Senior Vice President and
e Syntho democratizes data Chief Information Officer,
Cedars-Sinai Involvement access for researchers, startups Cedars-Sinai
Syntho participated in the Cedars-Sinai
and trainees. Broader, faster AI
Accelerator and subsequently completed a pilot
development means better clinical
with Cedars-Sinai. The institution specifically
tools reaching patients sooner.
cited Syntho as a tool to lower barriers for clinical
researchers, speed up study launch and sunset,
Financial Impact
and enable students to use synthetic data
e A single Syntho deployment can
for learning—goals now integrated into Cedars-
save over $10,000 per research
Sinai’s Digital Innovation Platform strategy.
project by compressing timelines
from years to months.
17
Page 18
CASE STUDY IMPACT
REPORT
2026
AEVICE HEALTH
Focus Area Respiratory Care
Category Device and Digital Health
Unique Value
e Detects wheezing, tracks
respiratory and heart rate,
“ We are on a
mission to bring
and alerts clinicians to early the same level
Opportunity Early detection of chronic
respiratory diseases
deterioration — enabling proactive of care from
intervention before hospitalization
could benefit more than
becomes necessary.
the hospital
500 million people.
straight into
Early Wins patients’ homes,
Aevice Health’s flagship product, the AeviceMD,
e Secured two U.S. FDA clearances.
is the world’s smallest smart wearable empowering
stethoscope, designed for continuous, non- e CES Innovation Awards 2023 –
invasive monitoring of lung sounds at home.
them to achieve
Best of Innovation in Digital Health.
AeviceMD enables patients, including children better control
Paired with the AeviceMD wearable e Digital Health Awards 2023 Quarter-
and adults, to receive hospital-quality respiratory over their
”
stethoscope, the AeviceMD app delivers finalist: Best in Class for Pediatric-
insights from home.
actionable insights into patients’ asthma
or COPD status, enabling more informed
Adolescent Care Innovation. conditions.
and proactive disease management.
Cedars-Sinai Involvement Social Impact Adrian Ang
Aevice Health participated in the Cedars-Sinai CEO and co-founder,
e Home-based monitoring allows
Accelerator, where it refined its U.S. product- Aevice Health
patients to avoid unnecessary ER
market fit and product launch strategy with
visits, receive timely adjustments
guidance from Cedars-Sinai clinical leaders
to their care plan and maintain
and hospital administrators. Cedars-Sinai
independence.
Medical Center is both an investor and a
deployment site for the AeviceMD device.
Financial Impact
e For a cohort of 5,000 patients, a
10% reduction in hospitalizations
could reduce acute care costs by
more than $5 million per year.
18
Page 19
CASE STUDY IMPACT
REPORT
2026
AIDIN
Focus Area Post-acute care
Unique Value
“ Aidin’s
3 hours
e Enables performance-based
Category Care Coordination and referrals integrated with major
platform will
Revenue Cycle EMRs such as Epic that align allow us to
Opportunity Post-acute care costs
hospital incentives with patient standardize
outcomes.
Average daily staff time the U.S. health system workflows
saved per team member $45 billion per year.
Early Wins to reduce
e Deployed in leading health
administrative
1,500
Aidin is a care coordination platform that
systems such as Mount Sinai and
empowers patients and hospitals to make
Yale New Haven Health.
burden and
data-driven decisions during discharge
planning. Its marketplace model introduces
decrease
Social Impact variability in
transparency and performance metrics into the
Additional new patients as a e A reduction in readmissions by
traditionally opaque post-acute care referral
more than 20% directly impacts
care transitions
result of increased capacity process.
patient quality of life. across the
$4.1B
Cedars-Sinai Involvement continuum of
”
Financial Impact
Aidin is part of the Cedars-Sinai Accelerator
e Delivered nearly $8 million in cost
care.
portfolio, with commercialization support and
savings at St. Luke’s University
ongoing investment from Cedars-Sinai Health
Health Network in a single year.
Jeannine Nylaan,
Healthcare spend directed Ventures. The partnership has supported MSN, RN
deployment across leading health systems, e A one-third day reduction in Executive Director of Care
to high-quality care Management, AdventHealth
including UCLA Health, Vanderbilt Health, average length of stay per
Mount Sinai Health System and Yale New implemented patient adds
Haven Health, leveraging Cedars-Sinai’s thousands of available bed-days
network and credibility. per year.
19
Page 20
CASE STUDY IMPACT
REPORT
2026
Movement exercises KNEU HEALTH
“
Tap an option below to see your average
Unique Value This is a
Focus Area Parkinson’s and Dementia
symptom measurement throughout the e Kneu Health’s platform
week. If you prefer not to see this, you can Category Digital Health (SaMD) transforms everyday smartphone
really interesting
navigate back.
interactions into clinical opportunity to
Opportunity Makes earlier intervention
and personalized care
intelligence. move monitoring
On / Off possible without requiring and care for a
Early Wins
100 new hardware.
75 e Recipient of the 2024 NHS H&J chronic condition
National Award for Digitizing like Parkinson’s
50
25 Kneu Health is a spinout from the University of
Patient Care.
Jun Jun Jun Jun Jun
0
Oxford and is pioneering smartphone-based out of the
02 09 16 23 30 solutions to transform Parkinson‘s Disease e Secured contracts with NHS
and dementia. Its platform turns everyday
hospital clinic
hospitals in the UK and finalizing
smartphones into FDA-registered, certified pilot agreements with three leading and into people’s
”
Balance medical devices using proprietary biomarkers U.S. healthcare systems. homes.
and AI-powered analytics.
Social Impact Dr. Andrew Graham
Walking
Cedars-Sinai Involvement e Reduced emergency admissions Consultant Neurologist,
for Parkinson’s patients by 1.2% Oxford Health NHS
Cedars-Sinai co-led Kneu Health’s $5.6 million
Foundation Trust,
seed round alongside Oxford Science compared to a 9% national increase
Reaction time a Kneu Health clinical
Enterprises. Kneu Health is deployed at (UK) during the same period. deployment partner
Cedars-Sinai as part of a validated clinical
Home Medication Logbook Insights
pilot, where it demonstrated 30% efficiency Financial Impact
gains in neurology clinics. e Generates $3,000 in savings
The Kneu Health app includes home-based per patient per year through
tests that measure balance, walking, dexterity,
reduced emergency visits and
tremor, reaction time and voice.
hospitalizations.
20
Page 21
CASE STUDY IMPACT
REPORT
2026
HEALTHLEAP
“
Unique Value AI tools that
Focus Area Malnutrition
e Unlike nurse-administered
Category Clinical SaaS screening tools, NutriLeap
continuously
analyzes medical history, body screen patient
Opportunity One in three hospital
patients in the U.S. suffer
measurements, lab results records and
and symptoms to flag subtle
from malnutrition, yet
at-risk patients.
surface risk in
only 6% are diagnosed.
real time are
88%
Early Wins exactly the
HealthLeap’s NutriLeap is an AI-powered
e At Cedars-Sinai, 39% more
clinical nutrition decision support app that helps
malnutrition cases were
kind of clinical
dietitians automate medical calculations and
provides data-driven recommendations for
diagnosed using the software decision support
improving patient nutrition care. The
with a one- to two-day shorter dietitians
higher
”
length of stay.
solution aims to reduce hospital malnutrition by need.
streamlining clinical workflows and enhancing
sensitivity the quality of care for patients.
Social Impact
e Enables the identification
Peer-reviewed validation
study co-authored by
than nurse- Cedars-Sinai Involvement
of a significant number of
malnutrition cases that are
researchers at Cedars‑Sinai,
Johns Hopkins and Stanford
administered NutriLeap was deployed at Cedars-Sinai as
a commercial implementation. A validation
unidentified using traditional Health—published in support
of NutriLeap’s AI model
screening methods.
malnutrition study was co-authored by researchers (AUROC 0.92 on Day 1
hospitalization data)
at Cedars‑Sinai, Johns Hopkins, and
Financial Impact
screening Stanford Health. HealthLeap also received
e Generated over $9 million in
commercialization support and continued
single-site revenue savings
investment from Cedars-Sinai, which is listed
and $10.5 million in total annual
among its innovation partners.
financial impact at Cedars-Sinai
alone.
21
Page 22
Why
Cedars-Sinai?
Cedars-Sinai’s world-class
research enterprise drives
a continuous pipeline of
discovery, translating
scientific insight into
practical applications. This
depth of expertise enables
rapid validation, strong
clinical evidence and a
steady flow of innovations
ready for development,
commercialization and
real-world impact.
22
Page 23
HEALTH
VENTURES
Cedars-Sinai Health Ventures
(CSHV) is the strategic venture arm of Cedars-Sinai. CSHV focuses
on investments in software, AI, health information technology and
tech-enabled services companies that have achieved product/
market fit and share our mission to transform healthcare delivery.
“ By rapidly deploying
these innovations
enterprise-wide, we
ensure that cutting-
CSHV typically invests at Series A but can invest at Seed or Series B.
We look for strategically and mission-aligned businesses where we edge solutions reach our
can implement and deploy core product rapidly, enterprise-wide,
then pursue further collaboration on product extension. A pilot or
clinicians and patients
commercial agreement is not required pre-investment, but a clear
line of sight to commercial engagement with key stakeholders is
essential. CSHV maintains flexibility in deal structure.
quickly, delivering “
measurable impact where
it matters most.
MAUREEN BURGESS, JD
Partner, Cedars-Sinai
Health Ventures
23
Page 24
CASE STUDY IMPACT
REPORT
2026
AMAE HEALTH
Focus Area Integrated severe mental
illness (SMI) care
Unique Value
e The concept integrates
psychiatry, primary care, therapy,
“ Amae is
advancing a
Category Outpatient Care health coaching, peer support, model of care that
Opportunity Nearly 5% of U.S. adults
and social work in a single prioritizes clinical
outpatient clinic.
live with SMI, yet less than excellence and
A New Standard half receive adequate
for SMI Care Early Wins compassionate,
treatment.
Standard Amae
e Four fully deployed clinics in
patient-centered
of Care Health Los Angeles, Raleigh, New York,
Amae Health is a value-based care provider
and Los Altos, with additional sites
services. By
focused on SMI, delivering psychiatry-led, long-
30-day ER
readmissions 23% 4% term outpatient care through a multidisciplinary
anticipated over time. combining an
model that includes therapy, primary care and e Signed value-based contracts outstanding team
social support, while advancing research to with top payers, including Carelon, of clinicians with
15 1.5
Average
length of transform outcomes and set a new standard Alliance Health, BCBS, Aetna and
stay per
days days for SMI treatment across diverse communities
a thoughtful
readmission Optum.
nationwide. approach to
Social Impact long-term care,
Medication
adherence 5.3% 90% Cedars-Sinai Involvement e Amae Health keeps patients
Amae is delivering
Cedars-Sinai invested $6 million in Amae engaged (7% dropout vs. 70%
Health, building on a two-year partnership national average after 1 to 2 visits) outcomes that
Engagement 70% 7%
dropout dropout
that began when the company opened its first through compassionate, consistent
outpatient care.
are both
Los Angeles clinic. The collaboration provides
after significant and
”
1–2 visits continued investment, clinical credibility,
a strong referral ecosystem in Los Angeles Financial Impact sustainable.
and validation of Amae Health’s model as e A 4% 30-day readmission rate
a potential center of excellence for SMI care represents dramatic reductions in Itai Danovitch, MD
Chairman, Department of
within the Cedars-Sinai network. ER and inpatient spend—the most
Psychiatry and Behavioral
expensive care settings. Neurosciences, Cedars-Sinai
24
Page 25
CASE STUDY IMPACT
REPORT
2026
Rx REDEFINED
“
Unique Value When
Focus Area Medical Supply
e The platform handles compliance,
Distribution
medical billing requirements and
patients
Category Outpatient Care patient eligibility verification for leave with the
Opportunity A fragmented Durable
every order. right product,
Medical Equipment industry
Early Wins properly fitted,
valued at over $600 billion
e In the last year, Rx Redefined grew and with
leaves providers burdened
with inefficiencies.
booked sales 10-fold and increased instructions from
its physician population by 450%.
a provider they
Rx Redefined is a healthcare technology e To date, the platform has enabled
company that streamlines how patients receive
already trust —
physicians to distribute millions of
recurring-use medical supplies by enabling medical products to their patients. rather than
physicians to distribute these supplies directly getting a box
to their patients. Founded in 2018, the company Social Impact
removes traditional intermediaries, improving e Patient noncompliance with
mailed to them
patient experience, access and compliance medical equipment drives weeks later—
while unlocking a new revenue stream for preventable complications and their compliance
providers. readmissions. By keeping supply
is dramatically
”
distribution within the physician’s
Cedars-Sinai Involvement office, Rx Redefined improves better.
Rx Redefined helps physicians distribute
recurring-use medical supplies directly to Cedars-Sinai is a commercialization and education, adherence and
patients, reducing delays and improving access investment partner for Rx Redefined. The outcomes for patients. Physician partner
to needed products. Rx Redefined platform
platform’s physician-centered model aligns
with Cedars-Sinai’s focus on integrated care Financial Impact
delivery and reducing friction in patient- e The platform removes costly
physician relationships. intermediaries, creating savings
for payers while generating new
revenue for physician practices.
25
Page 26
CASE STUDY IMPACT
REPORT
2026
HEALTH NOTE
“
Unique Value Health Note
Focus Area Patient Access
e The clinical decision-tree approach
Category Digital Health is integrated into the electronic
is solving one
medical record rather than relying of the single
Opportunity Manual intake delays
on traditional questionnaires which biggest pain
70%
throughput, reduces
need to be input into the patient’s
patient satisfaction,
medical record manually.
points in the
resolution rate and burdens clinical staff.
without human transfer healthcare
Early Wins system — the
Health Note is a clinician-founded AI platform for
e Deployed across more than 300
80%
patient access across voice, text and web. Health
clinical sites across the U.S.
physician
Note’s Access AI handles scheduling, refills and
reduction burnout
”
patient cases with frictionless, platform-agnostic e More than 500,000 patient interactions
in average hold times integration into electronic medical records. By per month across voice, text and web. epidemic.
restoring meaningful clinical time, Health Note
50%
helps physicians dedicate more attention to Social Impact Jill Kalman, MD
Senior Vice President
each patient interaction. e Thousands of hours of clinical staff
and Chief Medical Officer,
reduction time redirected from phones to Northwell Health—
in abandoned calls Cedars-Sinai Involvement in-person patient care. Health Note Series A investor
Cedars-Sinai Health Ventures was an early and clinical deployment
e Expanded after-hours patient access
partner
investor in the company. Health Note is
without adding headcount
actively deployed throughout the Cedars‑Sinai
network.
Financial Impact
e Rapid ROI, driven by lower labor
costs, higher throughput and
improved patient satisfaction.
e An 80% reduction in provider
documentation time translates to
direct, measurable FTE cost savings.
26
Page 27
CASE STUDY IMPACT
REPORT
2026
REGARD
“
Unique Value
Focus Area AI Diagnostic Support Regard has
e The platform combines
Category Outpatient Care advanced AI with deep clinical been a game-
understanding to automate changer, as it
Opportunity A single patient record
complex medical coding with
contains 50,000 data surfaces critical
unmatched accuracy.
points on average, 97% information
of which goes unseen.
Early Wins that may
e Deployed in Cedars-Sinai, Banner
Regard is an AI-powered clinical co-pilot that have been
Health, Sentara Health System,
helps physicians diagnose conditions and
WakeMed Health and Hospitals, missed, directly
generate documentation directly within the
electronic medical record. By analyzing patient
and more. impacting
records, it surfaces potential missed diagnoses, e Regard raised $61 million and patient care
streamlines clinical workflows and improves signed 25 active commercial without adding
billing accuracy with the goal of reducing contracts.
extra work for
”
administrative burden and helping hospitals
support accurate revenue capture while Social Impact doctors.
enhancing patient care. e Physicians using Regard’s system
reported saving up to 10 minutes David Kirk, MD
Chief Clinical Integration
Cedars-Sinai Involvement per patient after implementation.
Officer, WakeMed Health
Cedars-Sinai Health Ventures is an investor. and Hospitals
Cedars-Sinai Medical Center and Cedars-Sinai Financial Impact
Marina del Rey Hospital were among Regard’s e Using Regard’s platform has
earliest major health system deployments. generated over $150 million in
net new revenue for users.
27
Page 28
Why
Cedars-Sinai?
A broad and diverse
patient population
provides rich clinical insight
and real-world context.
This diversity strengthens
research relevance,
supports inclusive study
design and ensures
innovations are developed,
tested and refined to
meet the needs of varied
populations and care
settings.
28
Page 29
TEAM
To learn more about our team,
scan the QR code or visit
cedars-sinai.edu/research/
technology-innovations/team.html
DAVID M. WRIGLEY JAMES D. LAUR, JD NIRDESH K. GUPTA, PhD MAUREEN BURGESS, JD
Executive Vice President Senior Vice President, Managing Partner, Executive Director,
and Chief Financial Officer, Intellectual Property and Cedars-Sinai Intellectual Cedars-Sinai Health Ventures
Cedars-Sinai Health System Health Ventures Property Company
JULIEN BROHAN, MS, CLP ALEX CHAI, JD WENYUE DU, PhD KINSHUK KOCHER, MBA PETER S. PARK, JD OMAR PEREZ
Director, MedTech Ventures, Executive Director, Director, Biotech Ventures, Director, Venture Investing, Director, Business Operations, Manager, Portfolio Business Affairs,
Cedars-Sinai Tech Ventures Tech Ventures Legal Cedars-Sinai Tech Ventures Cedars-Sinai Tech Ventures Cedars-Sinai Tech Ventures Cedars-Sinai Accelerator+
ROHIT RAJKUMAR ERIC R. SEE SAMANTHA SHOBASH COLIN TAN KOEN VAN BREUGEL KEVIN WINSTON
Director, Business Development, Executive Director, Manager, Program Operations, Investment Director, Investment Director, Director, Business Development
Cedars-Sinai Health Ventures Tech Ventures Operations Cedars-Sinai Accelerator+ Coronet Ventures (Singapore) Coronet Ventures (Netherlands) and Programs,
Cedars-Sinai Tech Ventures
34
29
Page 30
GLOBAL IMPACT IMPACT
REPORT
2026
Cedars-Sinai Technology
Ventures has been building SINGAPORE
international relationships
“
for more than two decades,
helping to identify Our
and nurture promising partnership with
biotechnology partners
and bring innovative
Cedars-Sinai
medical solutions to patients helps promising
worldwide. Some of these UK healthcare
relationships have evolved
into significant partnerships
startups take
and investments, extending a critical leap
our impact globally. into the U.S.
KEY INTERNATIONAL
THE UNITED market, pairing
KINGDOM
MARKETS commercial and
e Singapore clinical insights
e The Netherlands with real-world
e The United Kingdom
opportunities
to validate
18 portfolio
companies
and refine their
technologies.
”
3
THE
commercial NETHERLANDS Heather Roxborough
contracts at Senior Partner
Cedars-Sinai Head of HealthTech
Oxford Science Enterprises
13
strategic
partnership
initiatives
30
Page 31
OUTRO
Grounded in a tradition of service and
innovation, Cedars‑Sinai Technology
& Health Ventures drives forward with
a clear purpose: to do well by doing
good—working with our partners to
advance discoveries that improve
lives while honoring a legacy rooted in
compassion, community and care.
© 2026 CEDARS-SINAI